SCHEMBL3879014

SCHEMBL3879014

Cc1cc(C(=O)N2CCC(c3nc4c(s3)CCN(C3CCC3)CC4)CC2)ccn1

nearest known ligand 0.44

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
PROKR1 Q8TCW9 3/20 0.44
UBE2M P61081 7/20 0.43
DCUN1D1 Q96GG9 7/20 0.43
LMNA P02545 1/20 0.43
L3MBTL3 Q96JM7 7/20 0.41
L3MBTL1 Q9Y468 6/20 0.41
ALDH1A1 P00352 1/20 0.39
GAA P10253 1/20 0.39
GFER P55789 1/20 0.39
TP53 P04637 1/20 0.38
TP53BP1 Q12888 2/20 0.38
MBTD1 Q05BQ5 1/20 0.37
L3MBTL4 Q8NA19 1/20 0.37
CNR1 P21554 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3880889 0.87 UBE2M (0.59) UBE2MDCUN1D1LMNAL3MBTL3L3MBTL1
SCHEMBL3880372 0.87 L3MBTL3 (0.45) UBE2MDCUN1D1L3MBTL3L3MBTL1TP53BP1
SCHEMBL3879360 0.87 UBE2M (0.55) UBE2MDCUN1D1LMNAL3MBTL3L3MBTL1
SCHEMBL3879089 0.86 KDM4E (0.51) UBE2MDCUN1D1LMNAL3MBTL3L3MBTL1
SCHEMBL3879400 0.86 L3MBTL3 (0.40) UBE2MDCUN1D1LMNAL3MBTL3L3MBTL1
SCHEMBL3878900 0.85 HRH3 (0.37) UBE2MDCUN1D1LMNAL3MBTL3L3MBTL1
SCHEMBL3879018 0.84 UBE2M (0.42) PROKR1UBE2MDCUN1D1LMNAALDH1A1
SCHEMBL3882382 0.83 L3MBTL3 (0.44) UBE2MDCUN1D1LMNAL3MBTL3L3MBTL1
SCHEMBL3881839 0.83 HSD11B1 (0.43) UBE2MDCUN1D1LMNAL3MBTL3L3MBTL1
SCHEMBL3880051 0.83 L3MBTL1 (0.54) UBE2MDCUN1D1LMNAL3MBTL3L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1858900-B1 FUSED THIAZOLE DERIVATIVES HAVING AFFINITY FOR THE HISTAMINE H3 RECEPTOR GLAXO GROUP LTD (GB) 2009-01-07 EP claimed
US-20080161289-A1 Fused Thiazole Derivatives Having Affinity for the Histamine H3 Receptor GLAXO GROUP LIMITED 2008-07-03 US claimed
EP-1858900-B1 FUSED THIAZOLE DERIVATIVES HAVING AFFINITY FOR THE HISTAMINE H3 RECEPTOR GLAXO GROUP LTD (GB) 2009-01-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080161289-A1 Fused Thiazole Derivatives Having Affinity for the Histamine H3 Receptor HRH3, HRH4, HRH2 PROKR1 672/4885UBE2M 4124/4885DCUN1D1 2343/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.